Energenesis Biomedical Co., Ltd. · TWSE:6657

Energenesis Biomedical — Investor Presentation (September 2020)

19 slides from Energenesis Biomedical's investor presentation, September 2020

  1. Slide 1: Energenesis Biomedical

    ae Z BS BA Energenesis > Biomedical

  2. Slide 2: 免責聲明

    免責聲明 • 本簡報及同時發佈之相關訊息內含有從公司內部與外部來源所取得的 預測性資訊，其中包括營運展望、財務狀況以及業務預測等內容。 • 本公司未來實際所發生的營運結果、財務狀況以及業務展望，可能與 這些預測性資訊所明示或暗示的預估有所差異。其原因可能來自於各 種因素，包括但不限於市場需求、價格波動、競爭情勢、國際經濟狀 況、供應鏈、匯率波動以及其他本公司所不能掌控的風險等因素，未 來若有任何變更或調整時，本公司並不負責隨時提醒或更新。 • 本公司並無就有關資料之可靠性、準確性或完備性作出任何明示或暗 示之聲明或保證，且對使用本簡報資料任何內容或因倚賴該等內容所 採取行動而直接或間接引致之任

  3. Slide 3: Energenesis Biomedical At A Glance

    Energenesis Biomedical AT A GLANCE 公司創立時間 2012 35 員工人數 6 Ph.Ds and 20 Masters 2018年8月8日 登錄興櫃 3

  4. Slide 4: ENERGI platform - 全新治療機制

    ENERGI platform - 全新治療機制 ENERGI: 小分子藥物 全新藥理機制: 提升细胞能量 (ATP) 9H-purin-6-amine adenine 增加細胞電池數量 Salvage pathway ATP 非外來物質，安全無疑慮，無副作用 4

  5. Slide 5: 可提升紅血球內 ATP (CPDA blood bag)

    可提升紅血球內 ATP (CPDA blood bag)  5-10 mM in cells  2 x 1023 molecules in 65 kg human  Highly charged  Highly unstable  Synthesis in cytosol  Charged in mitochondria AMP AMP (Adenosine AMP (Adenosine monophosphate) monophosphate) (Adenosine monophosphate) ADP (Adenosine diphosphate) ATP (Adenosine

  6. Slide 6: ATP能使細胞正常運行

    ATP能使細胞正常運行 ATP concentration ATP Young cells threshold 1 Old cells + ENERGI Old cells ATP threshold 2 Shortage of ATP in cells as a cause of diseases G1m G1p S G2 M variable 6 hours 3 hours 0.5 hours Replenish of ATP by ENERGI may treat certain diseases TIME mitochondria Cell body nucleus 6 Modifie

  7. Slide 7: ENERGI能增加各種細胞中的ATP數量

    ENERGI能增加各種細胞中的ATP數量 The IHC staining against insulin in pancreas section Epithelial cells Hair follicle dermal papilla cells Neural cells 6 0 m in u t e s ** 200 ** ** T h e le v e l o f A T P ( % ) 150 ** ** Intracellular ATP (%) ** ** ** ** ** 100 * 100 50 0 0 Passage P5 P5 P16 P16 ENERGI ENERGI

  8. Slide 8: ENERGI 平台應用性廣泛

    ENERGI 平台應用性廣泛 F703EB Epidermolysis Bullosa 泡泡龍 F703VLU Venous Leg Ulcer 下肢靜脈 潰瘍 F703BS ATP↑ Bed Sore 褥瘡 ATP↑ ATP↑ 8

  9. Slide 9: 糖尿病足傷口潰瘍 (Diabetic foot ulcer, DFU)

    9 糖尿病足傷口潰瘍 (Diabetic foot ulcer, DFU) 未被滿足的慢性傷口醫療需求  糖尿病患者15-20% 併發DFU  DFU 患者 33%會被截肢  全球糖尿病足患者67,000,000人  截肢後五年死亡率超過 70% Source: Diabetes Care 2015 Oct; 38(10): 1852-1857 N. Engl. J. Med 2017 Jun 15;376(24)2367-2375, DG Armstrong, AJM Boulton, SA Bus www.podiatrytoday.com/healing-post-op-ampu

  10. Slide 10: 最新慢性傷口癒合手段 – 提升細胞內 ATP

    最新慢性傷口癒合手段 – 提升細胞內 ATP • Increase cellular ATP to accelerate • Actin is the cytoskeleton protein epithelial cell migration and further • The arrangement of actin which is essential for cell promote skin repair migration is ATP dependent Low energy status (low ATP) cell migrates slowly (skin repairs

  11. Slide 11: 目前糖尿病足潰瘍唯一用藥有安全疑慮

    目前糖尿病足潰瘍唯一用藥有安全疑慮 ENERGI-F703凝膠有潛力佔領DFU藥物市場 Regranex (Smith & Nephews) ENERGI-F703 gel shows better the only FDA approved DFU drug efficacy than Regranex Market share 100 F703 treatment period Safety ENERGI-F703 gel Regranex < 1% Placebo Closure Rate (%) 75 Regranex treatment period  Contains human

  12. Slide 12: ENERGI新藥平台開發現況

    ENERGI新藥平台開發現況 Discovery Lead opt. Pre-clinical Phase 1 Phase 2 Phase 3 NDA Market CODE INDICATIONS 藥物探索 最適化 臨床前開發 臨床一期 臨床二期 臨床三期 查驗登記 新藥上市 DERMATOLOGY DISEASES - 皮膚相 關 疾病 F703 Diabetic foot ulcer treatments (gel) 糖尿病足部潰瘍外用凝膠 F701 Alopecia treatments (tonic) 防止落髮外用液劑 F703VLU Venous leg ulcers treatm

  13. Slide 13: ENERGI-F701 tonic 唯一利用增加 ATP為機制的防止落髮藥品

    異常性落髮核准藥物皆有副作用 ENERGI-F701 tonic 唯一利用增加 ATP為機制的防止落髮藥品 正常毛囊週期 anagen catagen telogen Life time (80yrs) 二氫睪固酮 縮短毛囊週期 anagen 落建 (minoxidil) 柔沛 (finasteride) catagen telogen hair loss Life time (80yrs)  促生新髮 X 促生新髮 ENERGI-F701 增加細胞 ATP，恢復毛囊週期 X 防止落髮  防止落髮 anagen X 初期使用會顯著落髮 X 影響性功能! catagen 且須終生使用! te

  14. Slide 14: ENERGI較REGAINS更有效及快速減少落髮

    ENERGI較REGAINS更有效及快速減少落髮 • The hair loss percentage compared to week 0 (100%) • ENERGI-F701 reached 60% hair loss at week 4 ; Regaine reached 60% hair loss at week 12 • Fast effeteness was observed at week 4 with a significant difference compared with Regaine Hair loss percentage after treatment 100

  15. Slide 15: ENERGI可防止神經元細胞中的蛋白質聚集

    ENERGI可防止神經元細胞中的蛋白質聚集 Science. 2017 May 19;356(6339):753-756. Wild type PD mutant PD mutant neuron Neuron (A53T) Neuron (A53T) ATP as a biological hydrotrope. - ENERGI - ENERGI + ENERGI Patel A1, Malinovska L1, Saha S1, Wang J1, Alberti S1, Krishnan Y2, Hyman AA3. 1. Max Planck Institute of Molecula

  16. Slide 16: ENERGI可維持運動神經元的完整性並恢復PD模型小鼠的行為

    ENERGI可維持運動神經元的完整性 並恢復PD模型小鼠的行為 Challenging beam transversal PQ ENERGI PQ treated PQ Treated Fig. The effect of ENERGI-F705 on the expression of + tyrosine hydroxylase in the substantia nigra of the ENERGI Paraquat (PQ) -treated C57BL/6 mouse. 16

  17. Slide 17: 華安沿革與短期規劃

    華安沿革與短期規劃 額定資本額: 10 億 實收資本額：5.86 億 工業局推薦函 公司設於輔大 生技新藥公司核准 公開發行2017/08 興櫃 2018/08 2012-2015 2016 2017 2018 2019 2020 FDA Phase II 獲准執行 A+企業創新研發淬鍊計畫補助 FDA Phase III IND TFDA Phase III IND ENERGI-F703 DFU TFDA Phase II准執行 台北市產業發展獎勵補助 糖尿病足潰瘍凝膠 解盲 開始收案 FDA Phase II 獲准執行 TFDA Phase II 獲准執行 ENERGI-F701 防止落

  18. Slide 18: 經營團隊

    經營團隊 Founder, Vice Chairman & CEO VP & Director of the General Administrative Division - Professor, Fu Jen Catholic University - MSc, Finance, Fu Jen Catholic University - PostDoc, University of S. California - IPO division of Taiwan International Securities, - PhD, National Taiwan University the fi

  19. Slide 19: Healing requires energy, here we provide.

    Healing requires energy, here we provide.

Energenesis Biomedical — Investor Presentation (September 2020) on 6ix